ALT FY 2021 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena

ALTAltimmune, Inc.

$353M

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-46.1% YoY

Gross Profit

$4M100.0% margin

Operating Income

-$97M-2197.6% margin

Net Income

-$97M-2201.6% margin

EPS (Diluted)

$-2.35

Cash Flow

Operating Cash Flow

-$78M

Free Cash Flow

-$91M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$219M

Total Liabilities

$20M

Stockholders' Equity

$199M

Cash & Equivalents

$190M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$8M	-46.1%
Gross Profit	$4M	-$25M	+117.4%
Operating Income	-$97M	-$55M	-76.9%
Net Income	-$97M	-$49M	-98.0%